Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.
Matsumoto A, Yatsuhashi H, Nagaoka S, Suzuki Y, Hosaka T, Tsuge M, Chayama K, Kanda T, Yokosuka O, Nishiguchi S, Saito M, Miyase S, Kang JH, Shinkai N, Tanaka Y, Umemura T, Tanaka E. Matsumoto A, et al. Among authors: miyase s. Hepatol Res. 2015 Dec;45(12):1195-202. doi: 10.1111/hepr.12488. Epub 2015 Feb 4. Hepatol Res. 2015. PMID: 25594111
Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study.
Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, Toyoda H, Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y. Miyamoto H, et al. Among authors: miyase s. Hepatol Res. 2024 Dec;54(12):1215-1225. doi: 10.1111/hepr.14092. Epub 2024 Jul 11. Hepatol Res. 2024. PMID: 38990762
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Fukubayashi K, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: miyase s. Cancers (Basel). 2023 Mar 2;15(5):1568. doi: 10.3390/cancers15051568. Cancers (Basel). 2023. PMID: 36900359 Free PMC article.
Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E. Matsumoto A, et al. Among authors: miyase s. J Gastroenterol. 2018 Feb;53(2):247-257. doi: 10.1007/s00535-017-1360-z. Epub 2017 Jun 20. J Gastroenterol. 2018. PMID: 28634723 Clinical Trial.
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E. Matsumoto A, et al. Among authors: miyase s. J Gastroenterol. 2020 Oct;55(10):977-989. doi: 10.1007/s00535-020-01707-6. Epub 2020 Jul 14. J Gastroenterol. 2020. PMID: 32666202
19 results